{
    "info": {
        "nct_id": "NCT03309111",
        "official_title": "A Phase 1, First-in-Human, Multicenter, Open-Label, Two-Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects With Previously Treated Multiple Myeloma",
        "inclusion_criteria": "* Documented diagnosis of multiple myeloma with measurable disease (serum, urine, or free light chain) per International Myeloma Working Group (IMWG) criteria, including non-secretory or oligo-secretory multiple myeloma which has relapsed after or is refractory to prior therapies, including proteasome inhibitors (PIs), immunomodulators (IMiDs) and anti-CD38 targeted therapies (daratumumab, isatuximab).\n* Eastern Cooperative Oncology Group (ECOG) performance-status score of 2 or less and 1 or less (for France).\n* Adequate hematologic, renal, and hepatic functions\n* Seronegative for hepatitis B antigen; positive hepatitis B tests can be further evaluated by confirmatory tests, and if viral load is negative, the subject can be enrolled.\n* Seronegative for hepatitis C antibody; if positive, then further test for the presence of antigen by hepatitis C virus polymerase chain reaction (HCV PCR). If HCV antigen tests are negative, then the subject can be enrolled.\n* Oxygen saturation level ≥92% on room air.\n* Left ventricular ejection fraction (LVEF) ≥50% and no pericardial or pleural effusion at Screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Active central nervous system involvement\n* Exposure to daratumumab or isatuximab within 2 months prior to the start of study treatment\n* Active plasma cell leukemia\n* Active infectious disease\n* Clinically significant cardiovascular and respiratory conditions\n* History of HIV infection\n* Subjects requiring prohibited concomitant medications",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Adequate hematologic, renal, and hepatic functions",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic ... functions",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal ... functions",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... hepatic functions",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented diagnosis of multiple myeloma with measurable disease (serum, urine, or free light chain) per International Myeloma Working Group (IMWG) criteria, including non-secretory or oligo-secretory multiple myeloma which has relapsed after or is refractory to prior therapies, including proteasome inhibitors (PIs), immunomodulators (IMiDs) and anti-CD38 targeted therapies (daratumumab, isatuximab).",
            "criterions": [
                {
                    "exact_snippets": "Documented diagnosis of multiple myeloma",
                    "criterion": "multiple myeloma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable disease (serum, urine, or free light chain) per International Myeloma Working Group (IMWG) criteria",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "serum",
                                "urine",
                                "free light chain"
                            ]
                        },
                        {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "IMWG"
                        }
                    ]
                },
                {
                    "exact_snippets": "including non-secretory or oligo-secretory multiple myeloma",
                    "criterion": "non-secretory or oligo-secretory multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "non-secretory",
                                "oligo-secretory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "which has relapsed after or is refractory to prior therapies, including proteasome inhibitors (PIs), immunomodulators (IMiDs) and anti-CD38 targeted therapies (daratumumab, isatuximab)",
                    "criterion": "response to prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "relapsed_or_refractory",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior_therapies",
                            "expected_value": [
                                "proteasome inhibitors (PIs)",
                                "immunomodulators (IMiDs)",
                                "anti-CD38 targeted therapies (daratumumab, isatuximab)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance-status score of 2 or less and 1 or less (for France).",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance-status score of 2 or less",
                    "criterion": "ECOG performance-status score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "1 or less (for France)",
                    "criterion": "ECOG performance-status score (France)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Oxygen saturation level ≥92% on room air.",
            "criterions": [
                {
                    "exact_snippets": "Oxygen saturation level ≥92% on room air",
                    "criterion": "oxygen saturation level",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Seronegative for hepatitis C antibody; if positive, then further test for the presence of antigen by hepatitis C virus polymerase chain reaction (HCV PCR). If HCV antigen tests are negative, then the subject can be enrolled.",
            "criterions": [
                {
                    "exact_snippets": "Seronegative for hepatitis C antibody",
                    "criterion": "hepatitis C antibody",
                    "requirements": [
                        {
                            "requirement_type": "serostatus",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "if positive, then further test for the presence of antigen by hepatitis C virus polymerase chain reaction (HCV PCR). If HCV antigen tests are negative, then the subject can be enrolled.",
                    "criterion": "hepatitis C virus antigen (by HCV PCR)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Seronegative for hepatitis B antigen; positive hepatitis B tests can be further evaluated by confirmatory tests, and if viral load is negative, the subject can be enrolled.",
            "criterions": [
                {
                    "exact_snippets": "Seronegative for hepatitis B antigen",
                    "criterion": "hepatitis B antigen serostatus",
                    "requirements": [
                        {
                            "requirement_type": "serostatus",
                            "expected_value": "seronegative"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive hepatitis B tests ... if viral load is negative, the subject can be enrolled",
                    "criterion": "hepatitis B viral load",
                    "requirements": [
                        {
                            "requirement_type": "viral load",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) ≥50% and no pericardial or pleural effusion at Screening",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) ≥50%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no pericardial or pleural effusion at Screening",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "no pericardial or pleural effusion at Screening",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Subjects requiring prohibited concomitant medications",
            "criterions": [
                {
                    "exact_snippets": "Subjects requiring prohibited concomitant medications",
                    "criterion": "requirement for prohibited concomitant medications",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active plasma cell leukemia",
            "criterions": [
                {
                    "exact_snippets": "Active plasma cell leukemia",
                    "criterion": "plasma cell leukemia",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infectious disease",
            "criterions": [
                {
                    "exact_snippets": "Active infectious disease",
                    "criterion": "infectious disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exposure to daratumumab or isatuximab within 2 months prior to the start of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Exposure to daratumumab or isatuximab within 2 months prior to the start of study treatment",
                    "criterion": "exposure to daratumumab",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months prior to the start of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Exposure to daratumumab or isatuximab within 2 months prior to the start of study treatment",
                    "criterion": "exposure to isatuximab",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months prior to the start of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active central nervous system involvement",
            "criterions": [
                {
                    "exact_snippets": "Active central nervous system involvement",
                    "criterion": "central nervous system involvement",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of HIV infection",
            "criterions": [
                {
                    "exact_snippets": "History of HIV infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant cardiovascular and respiratory conditions",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiovascular ... conditions",
                    "criterion": "cardiovascular conditions",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant ... respiratory conditions",
                    "criterion": "respiratory conditions",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}